Probiodrug to
Attend and Present at European Conferences in May 2016
HALLE/SAALE,
Germany, 3 May 2016 - Probiodrug AG ("Probiodrug", Euronext:
PBD), a biopharmaceutical company developing novel therapeutic
solutions to treat Alzheimer's disease, announces that the company
is scheduled to attend the following conferences:
(1)
Bio€quity Europe 2016
10 - 11 May 2016, Scandic Hotel, Copenhagen, Denmark
Dr Hendrik
Liebers, CFO, to present on Tuesday, 10 May at 11:40 am CET in Ball
Room 1
Now in its 17th year, Bio€quity
Europe is a major industry event for financial dealmakers looking
for investor-validated life science companies and for
pharmaceutical licensing professionals to assess top prospects.
Bio€quity Europe has showcased more than 700 leading European
companies to thousands of investment and pharma business
development professionals. Delegates from over 20 nations attended
the event last year.
(2)
analytica 2016
10 - 13 May 2016, Messe Munich, Germany
Dr Hendrik
Liebers, CFO, to join the panel on Thursday, 12 May, at 03:30 pm
CET entitled: "Biotech and the stock exchange: A
marriage of convenience or elite partners?"
The analytica conference aims to
promote interactions between scientists and industry
representatives to enable interdisciplinary collaboration on an
international level. The Finance Day on Thursday, 12 May, will
enable biotech entrepreneurs to meet with investors. Speakers will
discuss the latest financing trends as well as collaborations
between big pharma and biotech companies. This year's program will
focus on which financing alternatives are best for companies and
tips on how to enter the US market.
###
For more
information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume
Brophy
Supriya Mathur, Eva Haas, Alexia Faure
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com
Notes to
Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam:
PBD) is a biopharmaceutical company focused on the development of
new therapeutic products for the treatment of Alzheimer's
disease.
Founded in 1997, the company
successfully developed a novel therapeutic concept for diabetes -
the DP4 inhibitors - which provided the basis for a novel class of
antidiabetics - the gliptins. Its core capabilities are based on
its long-standing expertise in the elucidation of the structure and
function of enzymes involved in the modification of proteins and
peptides, which play a central role in pathological conditions.
Today Probiodrug's aim is to
become a leading company in the development of Alzheimer's disease
treatments and to thereby provide a better life for Alzheimer's
disease patients. It has identified a new therapeutic concept
linked to disease initiation and progression. The development
approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a
therapeutic strategy to fight Alzheimer's disease. The Company has
medical use and composition of matter patents related to the
inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific
monoclonal antibodies, providing it, in the Company's view, with a
leading position in this field of research.
www.probiodrug.de
About Alzheimer's
disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, over 46 million people worldwide currently live with the
condition and this number is expected to increase to 132 million by
2050. Alzheimer's also has an estimated, global societal cost of
US$ 818 billion (World Alzheimer Report 2015).
Forward Looking
Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.